2013).We	 O
designed	 O
this	 O
study	 O
to	 O
evaluate	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
[P1]	 O
anlotinib	 O
[P2]	 O
combined	 O
with	 O
S-1	 O
as	 O
a	 O
third	 O
-	 O
line	 O
treatment	 O
for	 O
patients	 O
with	 O
stage	 O
IV	 O
NSCLC	 O
.	 O

2013).We	 O
designed	 O
this	 O
study	 O
to	 O
evaluate	 O
the	 O
efficacy	 O
and	 O
safety	 O
of	 O
anlotinib	 O
combined	 O
with	 O
[P1]	 O
S-1	 O
[P2]	 O
as	 O
a	 O
third	 O
-	 O
line	 O
treatment	 O
for	 O
patients	 O
with	 O
stage	 O
IV	 O
NSCLC	 O
.	 O

The	 O
patients	 O
will	 O
be	 O
treated	 O
with	 O
[P1]	 O
anlotinib	 O
[P2]	 O
and	 O
S-1	 O
;	 O
they	 O
will	 O
undergo	 O
computed	 O
tomography	 O
(	 O
CT	 O
)	 O
before	 O
the	 O
treatment	 O
,	 O
after	 O
two	 O
,	 O
four	 O
,	 O
and	 O
six	 O
cycles	 O
,	 O
and	 O
during	 O
follow	 O
-	 O
up	 O
every	 O
3	 O
months	 O
until	 O
disease	 O
progression	 O
or	 O
death	 O
.	 O

The	 O
patients	 O
will	 O
be	 O
treated	 O
with	 O
anlotinib	 O
and	 O
[P1]	 O
S-1	 O
[P2]	 O
;	 O
they	 O
will	 O
undergo	 O
computed	 O
tomography	 O
(	 O
CT	 O
)	 O
before	 O
the	 O
treatment	 O
,	 O
after	 O
two	 O
,	 O
four	 O
,	 O
and	 O
six	 O
cycles	 O
,	 O
and	 O
during	 O
follow	 O
-	 O
up	 O
every	 O
3	 O
months	 O
until	 O
disease	 O
progression	 O
or	 O
death	 O
.	 O

Previously	 O
used	 O
[P1]	 O
anlotinib	 O
[P2]	 O
or	 O
S-1	 O
2	 O
.	 O

Previously	 O
used	 O
anlotinib	 O
or	 O
[P1]	 O
S-1	 O
[P2]	 O
2	 O
.	 O

The	 O
required	 O
number	 O
of	 O
patients	 O
was	 O
estimated	 O
to	 O
be	 O
â‰¥29based	 O
on	 O
the	 O
objective	 O
response	 O
rate	 O
of	 O
[P1]	 O
anlotinib	 O
[P2]	 O
monotherapy	 O
.	 O

[P1]	 O
Anlotinib	 O
[P2]	 O
:	 O
orally	 B-DOSAGE
12	 I-DOSAGE
mg	 I-DOSAGE
once	 I-DOSAGE
-	 I-DOSAGE
a	 I-DOSAGE
-	 I-DOSAGE
day	 I-DOSAGE
before	 O
breakfast	 O
for	 O
two	 B-DOSAGE
consecutive	 I-DOSAGE
weeks	 I-DOSAGE
,	 O
then	 O
withdrawn	 O
for	 O
one	 O
week	 O
,	 O
with	 O
a	 O
21-day	 O
course	 O
of	 O
treatment	 O
.	 O

We	 O
believe	 O
that	 O
[P1]	 O
anlotinibin	 O
[P2]	 O
combination	 O
with	 O
chemotherapy	 O
would	 O
be	 O
an	 O
effective	 O
treatment	 O
strategy	 O
for	 O
patients	 O
with	 O
stage	 O
IV	 O
NSCLC	 O
.	 O

Therefore	 O
,	 O
we	 O
designed	 O
a	 O
prospective	 O
,	 O
phase	 O
II	 O
clinical	 O
trial	 O
to	 O
investigate	 O
the	 O
effectiveness	 O
and	 O
safety	 O
of	 O
[P1]	 O
anlotinibin	 O
[P2]	 O
combination	 O
with	 O
S-1	 O
;	 O
if	 O
this	 O
combination	 O
treatment	 O
is	 O
effective	 O
and	 O
welltolerated	 O
,	 O
then	 O
it	 O
may	 O
be	 O
used	 O
as	 O
a	 O
third	 O
-	 O
line	 O
treatment	 O
for	 O
patients	 O
with	 O
stage	 O
IV	 O
NSCLC	 O
.	 O

Therefore	 O
,	 O
we	 O
designed	 O
a	 O
prospective	 O
,	 O
phase	 O
II	 O
clinical	 O
trial	 O
to	 O
investigate	 O
the	 O
effectiveness	 O
and	 O
safety	 O
of	 O
anlotinibin	 O
combination	 O
with	 O
[P1]	 O
S-1	 O
[P2]	 O
;	 O
if	 O
this	 O
combination	 O
treatment	 O
is	 O
effective	 O
and	 O
welltolerated	 O
,	 O
then	 O
it	 O
may	 O
be	 O
used	 O
as	 O
a	 O
third	 O
-	 O
line	 O
treatment	 O
for	 O
patients	 O
with	 O
stage	 O
IV	 O
NSCLC	 O
.	 O